0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Does Aquaporin-4–Seronegative Neuromyelitis Optica Exist?

Michael Levy, MD, PhD1
[+] Author Affiliations
1Department of Neurology, Johns Hopkins University, Baltimore, Maryland
JAMA Neurol. 2014;71(3):271-272. doi:10.1001/jamaneurol.2013.5865.
Text Size: A A A
Published online

Extract

With the improvement in anti–aquaporin-4 (AQP4) assay sensitivity to near 90%,1 the concept of seronegative neuromyelitis optica (NMO) is being challenged. The widely accepted criteria for NMO proposed2 in 1999 and revised3 in 2006 define NMO as a disease localized to the optic nerves and spinal cord, which is not multiple sclerosis (MS). The anti-AQP4 antibody has always been a very highly specific biomarker for NMO but, owing to insensitive assays, seropositivity was initially considered only a supportive criterion. Seronegative NMO was intended to represent the same disease process as seropositive NMO but, for whatever reason, the anti-AQP4 antibody was not detectable at the time. During the past 8 years since the anti-AQP4 antibody biomarker was discovered and linked to NMO, the research field has focused intensely on the role of AQP4 as an immunopathogenic target.4 Supported by incremental advancements in the anti-AQP4 biomarker assay, the understanding of true NMO is expanding its localization to brainstem and cortical disease, while narrowing its population base to those who are seropositive for the anti-AQP4 antibody.5 That leaves neuroimmunologists with the question of whether a seronegative NMO disease actually exists?

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Author response. Neurology 2014;83(5):475-6.
Can Anti-AQP4 Antibody Damage the Blood-Brain Barrier? Eur Neurol Published online Oct 14, 2014.;
Jobs
brightcove.createExperiences();